DAWN Stock Recent News
DAWN LATEST HEADLINES
Day One Biopharmaceuticals is looking to file an NDA after successful glioma data. DAWN is well-financed, having been VC supported in the initial years.
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9 at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time.
Day One Biopharmaceuticals declared strong data in relapsed glioma in June. The company has strong cash position.
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a panel discussion at the 2022 Wedbush PacGrow Healthcare Virtual Conference. The panel entitled “Bullseye - Targeted Oncology - Finding Needles in Plain Sight” will be held on Tuesday, August 9 at 10:55 a.m. ET.
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.
A giant run-up on Monday could be the beginning of a much larger bull run.
Today's announcement of positive clinical trial results for a key pediatric tumor drug has DAWN stock more than doubling on Monday. The post Why Is Day One Biopharmaceuticals (DAWN) Stock Up 103% Today?
Day One Biopharmaceuticals (NASDAQ: DAWN) shares are surging on initial data from the first 22 evaluable patients in the Phase 2 FIREFLY-1 trial for tovorafenib (DAY101) in relapsed or progressive pediatric low-grade glioma (pLGG), the most common brain tumor diagnosed in children. .